AI
BIIB icon

ArchPoint Investors’s Biogen BIIB Stock Holding History

ArchPoint Investors’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-11,232
Closed -$3.05M – 154
2017
Q2 		$3.05M Buy
11,232
+4,812
+75% +$1.27M 0.97% 25
2017
Q1 		$1.75M Sell
6,420
-280
-4% -$79.2K 0.66% 29
2016
Q4 		$1.9M Buy
+6,700
New +$1.99M 1.12% 24

Other funds holding BIIB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

ArchPoint Investors's BIIB Position: Q3 2017 in Review

ArchPoint Investors sold out of Biogen (BIIB) in Q3 2017, closing a stake of 11,232 shares — an estimated $3.05M sold.

ArchPoint Investors first reported a position in BIIB in Q4 2016 and held it in 3 quarters. The position peaked at $3.05M in Q2 2017. 1,015 funds tracked by Wall St. Rank hold BIIB as of Q3 2017.

  • ArchPoint Investors reported no remaining Biogen position as of Q3 2017 after selling out during the quarter.
  • ArchPoint Investors sold 11,232 Biogen shares in Q3 2017, an estimated $3.05M.
  • ArchPoint Investors first reported a position in Biogen in Q4 2016 and held it in 3 quarters.
  • ArchPoint Investors's Biogen position peaked at $3.05M in Q2 2017.
  • 1,015 funds tracked by Wall St. Rank held Biogen as of Q3 2017.

Based on ArchPoint Investors's 13F filing for Q3 2017, filed 14 Nov 2017.